MedTrace Logo

Plasma Protein Binding Characteristics of Voriconazole

NCT01812473 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2015-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the influence of hypoalbuminemia on the protein binding characteristics of the antifungal drug voriconazole in ICU patients.

Conditions

  • Focus of the Study:Protein Binding Characteristics of Voriconazole.

Interventions

OTHER

Blood sampling

During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Kim Vanstraelen, PharmD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01812473 on ClinicalTrials.gov